Werewolf Therapeutics Inc. (HOWL) carries a Roarable Rating of D (Sell) with 47/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
As of 2026-11-02, Werewolf Therapeutics Inc. (NASDAQ: HOWL) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 47/100 at a spot price of $0.99 (-10.35% 1D, market cap $53.5M). Pillar breakdown: Fundamental Cash Engine 4/20, Institutional 13F & Options Flow 13/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 15/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, HOWL ranks #354 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), HOWL carries a Roarable D (47/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, PLRX (Pliant Therapeutics Inc.) holds a D grade (44/100 RQD, P/E N/A, ROIC -35.0%, cap $53.3M) and HYPD (Hyperion DeFi Inc.) posts a D grade (50/100 RQD, P/E N/A, ROIC -35.0%, cap $54.1M). Among the 5-stock peer group, HOWL leads on earnings multiple (N/A) while HOWL leads on capital efficiency (-35.0% ROIC).
Per HOWL's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001785530), Werewolf Therapeutics Inc. generated $0 in revenue, -$60.8M in net income, and -$60.3M in free cash flow against $69.4M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
FRED Regime × Technicals: 68% of 52W Range • RSI-14 at 51.1 (NEUTRAL RANGE)
20D Institutional Volume Accumulation (±11.9% realized swing band)
Capital intensity & 0% operating margin leave 16 pts on the table
While HOWL currently carries a cautious 47/100 (D) rating due to Cash Engine Quality (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
Established market leader in Health Care with deep daily trading liquidity.
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($0.97) and Max Pain ($1.04) forces dealer call-delta covering toward $1.40.
Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
Werewolf Therapeutics Inc. (HOWL) dropped -10.35% to $0.99, trading at 68% of its 52-week range ($0.27 – $1.33). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
WALTHAM, Mass., Oct. 30, 2026 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated th
Werewolf Therapeutics, Inc. (the "Company" or "Werewolf") (NASDAQ:HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate
Gainers Neumora Therapeutics (NASDAQ:NMRA) shares rose 11.9% to $0.41 during Tuesday's after-market session. The market value of their outstanding shares is at $73.8 million. Pulmonx (NASDAQ:LUNG) stock increased
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on HOWL today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for HOWL. Explore sector supply chains on /butterfly.
Across 1016 tracked Health Care securities in the Roarable RQD universe, Werewolf Therapeutics Inc. (HOWL) ranks #354 by composite RQD confidence (47/100, grade D) and #740 by equity capitalization ($53.5M). Within this direct 5-issuer industry benchmark cohort, HOWL leads on earnings valuation at N/A trailing P/E, while HOWL leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. HYPD currently holds the highest overall quantitative score in the immediate peer group at 50/100 (D) compared with HOWL at 47/100 (D).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| HOWL
ACTIVE
Werewolf Therapeutics Inc. | D | 47/100 | — | — | -35.0% | -10.35% | $53.5M | Benchmark Subject |
| PLRX Pliant Therapeutics Inc. | D | 44/100 | — | — | -35.0% | -0.13% | $53.3M | /plrx-vs-howl → |
| HYPD Hyperion DeFi Inc. | D | 50/100 | — | 62.7% | -35.0% | -8.13% | $54.1M | /hypd-vs-howl → |
| CNTB Connect Biopharma Holdings Limited | D- | 35/100 | — | — | -35.0% | -3.97% | $52.6M | /cntb-vs-howl → |
| IBIO iBio Inc. | E | 23/100 | — | — | -35.0% | -5.52% | $52.3M | /ibio-vs-howl → |
In its most recent audited fiscal period (FY2025, filed 2025-12-31), Werewolf Therapeutics Inc. (HOWL) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$60.8M, operating cash flow of -$60.3M, and free cash flow of -$60.3M (-6.8% YoY). On the balance sheet, HOWL closed FY2025 with $69.4M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 3/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $0 | -$60.8M | -$60.3M | -$60.3M | $69.4M | — |
| FY2024 (FY) | 2024-12-31 | $0 | -$70.5M | -$56.2M | -$56.4M | $126.9M | — |
| FY2023 (FY) | 2023-12-31 | $0 | -$37.4M | -$32.6M | -$32.6M | — | — |
As of 2026-11-02, Werewolf Therapeutics Inc. (NASDAQ: HOWL) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 47/100 at a spot price of $0.99 (-10.35% 1D, market cap $53.5M). Pillar breakdown: Fundamental Cash Engine 4/20, Institutional 13F & Options Flow 13/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 15/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, HOWL ranks #354 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), HOWL carries a Roarable D (47/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, PLRX (Pliant Therapeutics Inc.) holds a D grade (44/100 RQD, P/E N/A, ROIC -35.0%, cap $53.3M) and HYPD (Hyperion DeFi Inc.) posts a D grade (50/100 RQD, P/E N/A, ROIC -35.0%, cap $54.1M). Among the 5-stock peer group, HOWL leads on earnings multiple (N/A) while HOWL leads on capital efficiency (-35.0% ROIC).
Per HOWL's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001785530), Werewolf Therapeutics Inc. generated $0 in revenue, -$60.8M in net income, and -$60.3M in free cash flow against $69.4M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
HOWL last traded at $0.99 (-10.35% on volume of 415,566 shares), positioning the stock +2.06% above its 50-day simple moving average ($0.97) and +45.59% above its 200-day simple moving average ($0.68). Across its 52-week range of $0.27 to $1.33, HOWL sits at the 67.9% percentile with a 14-day RSI of 51.1 (NEUTRAL RANGE) and an implied next-earnings move of ±11.9% ($1.00 to $1.11).
Why HOWL Stock dropped -10.35% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
To protect compute speed and zero-delay Cboe BZX data quality for active members, our current $9.95/month Roarable Pro cohort is 100% full. Join the priority waiting list below and we will notify you the moment the next batch of Pro accounts opens (and lock in your $9.95/mo rate).
Link your personal ChatGPT, Claude Desktop, or Cursor via Roarable's Model Context Protocol (`mcp.roarable.com`) to query all 5,289 stocks, inspect Butterfly supply chains, and trade your `$100K Arena` account.
Interrogate SEC 10-K/10-Q filings on demand and ask custom ticker, valuation, or short-thesis questions directly to any of our 8 specialized AI Quant Analysts.
Command our AI agents to sort and sift 5,289 stocks by custom formulas, follow multi-indicator technical & cash-flow setups, and send you instant Email/SMS breakout & downgrade alerts.
Unlock sub-second Cboe BZX streaming quotes, pre-market/after-hours delta scanners, instant SEC Form 4 insider cluster alerts, and unlimited portfolio stress-testing.
All 8 Roarable Analysts (Mara Quenwick, Devon Kess, Gideon Vane, Eliott Vance, Sorel Thorne, Corin Hale, Tessa Rane, and Felix Orven) are proprietary AI Quant Analysts and automated algorithmic specialists — not human financial advisors, fiduciaries, or registered broker-dealers. While one-to-many daily stock ratings and briefings are free, custom 1-on-1 Q&A, custom AI sifting/indicator alert agents, and personal ChatGPT/Claude MCP connections consume dedicated per-user compute and require a $9.95/month Roarable Pro membership. All AI outputs are for educational and research purposes only and never constitute individualized investment advice.
Enter your Google email below for instant 1-step account activation, daily A–E stock rating alerts, and immediate access to your $100,000.00 Virtual Cash Arena account (100% free — no credit card required).